Satu M. Mustjoki

Selective scoring of drug effects in multicellular co-culture systems

The paper introduces CES, a computational framework to score drug effects in multicellular co-culture systems, distinguishing between immunomodulatory effects and toxicity.

Multimodal immunopharmacologic screens identify drugs rewiring the cancer-immune interface

The paper identifies drugs that rewiring the cancer-immune interface by enhancing NK cell function and tumor susceptibility through multimodal screening approaches.

RUNX1 aberrations in blast-phase CML induce the RBP SPATS2L which promotes growth, survival and stress granule assembly

This study identifies SPATS2L as a mediator of growth and survival in RUNX1-mutant blast-phase CML through stress granule formation, suggesting it as a therapeutic target.

Deep single-cell immune and signaling profiles predict long term therapy response in chronic myeloid leukemia within hours

The paper uses mass cytometry to analyze immune and signaling profiles in CML patients within hours of TKI treatment to predict 12-month treatment response.

Patient-derived tumor explant models of tumor immune microenvironment reveal distinct and reproducible immunotherapy responses

The paper evaluates immunomodulatory drug responses in patient-derived tumor explant models of breast and renal cancer, finding reproducible gene expression and cytokine changes across models.

Predicting recognition between T cell receptors and epitopes using contextualized motifs

TCRconv predicts T-cell receptor-epitope recognition using a deep learning model and provides insights into T-cell dynamics in COVID-19 patients.

Histopathological Landscape of Molecular Genetics and Clinical Determinants in MDS Patients

This study uses deep learning to analyze bone marrow histopathology in MDS patients, linking morphological features to genetic and clinical outcomes.

Determining epitope specificity of T cell receptors with TCRGP

The paper introduces TCRGP, a Gaussian process method for predicting TCR epitope specificity, and applies it to scRNA+TCRβ data to identify HBV-epitope specific T cells in hepatocellular carcinoma patients.

Inferring immunological control mechanisms from TKI dose alterations in CML patients

The paper uses a mathematical model to classify CML patients based on immune response dynamics following TKI dose alterations, identifying different mechanisms for achieving treatment-free remission.